Patients with elevated baseline CRP and hypoalbuminemia may benefit from combination therapy (IVIG + GC), while those with high EOS% and low CRP levels could be prioritized for glucocorticoid monotherapy. This evidence concerns the gene CRP and Hypoalbuminemia.